medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-26-28-32medalphabet-3963Research ArticleПРАКТИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯPRACTICAL GASTROENTEROLOGYВозможности применения урсодезоксихолевой кислоты в практике гастроэнтеролога и терапевтаThe possibilities of using ursodeoxycholic acid in the practice of a gastroenterologist and therapisthttps://orcid.org/0000-0003-4391-2889КноррингГ. Ю.KnorringG. Yu.

Кнорринг Герман Юрьевич - к.м.н., доцент кафедры терапии, клинической фармакологии и скорой медицинской помощи лечебного факультета Научно-образовательного института клинической медицины имени Н.А. Семашко

Москва

Knorring German Yu. - PhD Med, associate professor at Dept of Therapy, Clinical Pharmacology and Emergency Medical Care

Moscow

knorring@mail.ruhttps://orcid.org/0000-0003-2487-5509СедякинаЮ. В.SedyakinaYu. V.

Седякина Юлия Владимировна - к.м.н., доцент кафедры терапии, клинической фармакологии и скорой медицинской помощи лечебного факультета Научно-образовательного института клинической медицины имени Н.А. Семашко

Москва

Sedyakina Yulia V. - PhD Med, associate professor at Dept of Therapy, Clinical Pharmacology and Emergency Medical Care

Moscow

sedyakinayulia@gmail.comКурджиеваС. С.KurdzhievaS. S.

Курджиева Светлана Сергеевна - ассистент кафедры терапии, клинической фармакологии и скорой медицинской помощи лечебного факультета Научно-образовательного института клинической медицины имени Н.А. Семашко

Москва

Kurdzhieva Svetlana S. - assistant at Dept of Therapy, Clinical Pharmacology and Emergency Medical Care

Moscow

kafedrakf@mail.ruФГБОУ ВО «Российский университет медицины» Минздрава РоссииРоссияRussian University of MedicineRussian Federation202410112024026«Практическая гастроэнтерология» (2)2832Copyright © Кнорринг Г.Ю., Седякина Ю.В., Курджиева С.С., 20242024Кнорринг Г.Ю., Седякина Ю.В., Курджиева С.С.Knorring G.Y., Sedyakina Y.V., Kurdzhieva S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3963

Актуальность. Урсодезоксихолевая кислота (УДХК) – природная гидрофильная желчная кислота, изначально нашедшая свое применение при лечении ряда заболеваний печени в качестве терапии первой линии. УДХК снижает секрецию холестерина в желчь и активно используется в лечении и профилактике желчнокаменной болезни; также УДХК обладает способностью стимулировать гепатобилиарную секрецию, что важно для пациентов с первичным билиарным холангитом (ПБХ) и первичным склерозирующим холангитом (ПСХ). Более поздние исследования показали плейотропность эффектов УДХК в плане воздействия на патофизиологические процессы в печени и всего гепатобилиарного комплекса, например, противовоспалительное и антифибротическое действие, иммуномодулирующий и антиканцерогенный эффекты. Еще более интересными и важными оказались сложные механизмы влияния УДХК на развитие и прогрессирование неалкогольной жировой болезни печени (НАЖБП) и, далее, на патогенетические взаимосвязи НАЖБП и кардиоваскулярной патологии. Статья рассматривает возможности применения УДХК при заболеваниях желудочно-кишечного тракта и, шире, возможности препарата во влиянии на НАЖБП и развитие и прогрессирование сердечно-сосудистых и метаболических заболеваний.

Relevance. Ursodeoxycholic acid (UDCA) is a natural hydrophilic bile acid, which initially found its use in the treatment of a number of liver diseases as a first–line therapy. UDCA reduces the secretion of cholesterol into bile and is actively used in the treatment and prevention of gallstone disease; UDCA also has the ability to stimulate hepatobiliary secretion, which is important for patients with primary biliary cholangitis and primary sclerosing cholangitis. More recent studies have shown the pleiotropy of the effects of UDCA, in terms of effects on pathophysiological processes in the liver and the entire hepatobiliary complex, for example, anti-inflammatory and antifibrotic effects, immunomodulatory and anticarcinogenic effects. Even more interesting and important were the complex mechanisms of the effect of UDCA on the development and progression of non-alcoholic fatty liver disease (NAFLD) and, further, on the pathogenetic relationships of NAFLD and cardio-vascular pathology. The article examines the possibilities of using UDCA in diseases of the gastrointestinal tract and, more broadly, the possibilities of the drug in influencing NAFLD and the development and progression of cardiovascular and metabolic diseases.

урсодезоксихолевая кислотахолестазжелчнокаменная болезньнеалкогольная жировая болезнь печенистеатогепатитursodeoxycholic acidcholestasischolelithiasisnon-alcoholic fatty liver diseasesteatohepatitisReferencesМаевская М.В. Урсодезоксихолевая кислота: уникальные свойства и клиническое применение. Медицинский совет. 2023; (8): 96–105. https://doi.org/10.21518/ms2023–136Maevskayа M.V. Ursodeoxycholic acid: unique properties and clinical applications. Meditsinskiy Sovet. 2023 8): 96–105. (In Russ.). https://doi.org/10.21518/ms2023–136Lonardo A., Sookoian S., Chonchol M. et al. Cardiovascular and systemic risk in no- nalcoholic fatty liver disease – atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013; 19 (29): 5177–5192.Lonardo A., Sookoian S., Chonchol M. et al. Cardiovascular and systemic risk in no- nalcoholic fatty liver disease – atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013; 19 (29): 5177–5192.Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66 (6): 1138–1153. https://doi.org/10.1136/gutjnl-2017-313884Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66 (6): 1138–1153. https://doi.org/10.1136/gutjnl-2017-313884Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015; 62 (Suppl. 1): 47–64.Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015; 62 (Suppl. 1): 47–64.Волынец Г. В., Хавкин А. И. Урсодезоксихолевая кислота и болезни печени. Лечащий врач. 2020; (6): 62–68. https://doi.org/10.26295/OS.2020.75.99.012Volynets GV, Khavkin AI. Ursodeoxycholic acid and hepatic diseases. Lechaschi Vrach. 2020; (6): 62–68. (In Russ.). https://doi.org/10.26295/OS.2020.75.99.012Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003; 72: 137–174.Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003; 72: 137–174.Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007 Oct; 24 (10): 1803–23.Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007 Oct; 24 (10): 1803–23.Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3 (6): 318–328. https://doi.org/10.1038/ncpgasthep0521Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3 (6): 318–328. https://doi.org/10.1038/ncpgasthep0521Ивашкин В. Т., Маев И.В., Баранская Е.К., Охлобыстин А.В., Шульпекова Ю.О., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению желчнокаменной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (3): 64–80. https://doi.org/10.22416/1382-4376-2016-26-3-64-80Ivashkin V.T., Mayev I.V., Baranskaya Y.K., Okhlobystin A.V., Shulpekova Yu.O., Trukhmanov A.S. et al. Gallstone disease diagnosis and treatment: guide- lines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26 (3): 64–80. (In Russ.). https://doi.org/10.22416/1382-4376-2016-26-3-64-80Güldütuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology. 1993; 104 (6): 1736–1744. https://doi.org/10.1016/0016-5085(93)90653-tGüldütuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology. 1993; 104 (6): 1736–1744. https://doi.org/10.1016/0016-5085(93)90653-tHeuman D.M., Bajaj R. S., Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J. Lipid Res. 1996; 37: 562–573.Heuman D.M., Bajaj R. S., Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J. Lipid Res. 1996; 37: 562–573.Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver, Hepatology. 2001; 33 (5): 1206–1216. https://doi.org/10.1053/jhep.2001.24034Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G. A., Keppler D., Paumgartner G., Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver, Hepatology. 2001; 33 (5): 1206–1216. https://doi.org/10.1053/jhep.2001.24034Rodrigues C.M., Fan G., Wong P.Y., Kren B. T., Steer C. J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998; 4 (3): 165–178.Rodrigues C.M., Fan G., Wong P.Y., Kren B. T., Steer C. J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998; 4 (3): 165–178.Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol Hepatol. 2005 Feb; 17 (2): 137–140. DOI: 10.1097/00042737-200502000-00001Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol Hepatol. 2005 Feb; 17 (2): 137–140. DOI: 10.1097/00042737-200502000-00001Castro R.E., Solá S., Ma X., Ramalho R.M., Kren B. T., Steer C.J., Rodrigues C.M. A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeoxycholic acid. J. Hepatol. 2005; 42: 897–906. https://doi.org/10.1016/j.jhep.2005.01.026Castro R.E., Solá S., Ma X., Ramalho R.M., Kren B. T., Steer C.J., Rodrigues C.M. A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeoxycholic acid. J. Hepatol. 2005; 42: 897–906. https://doi.org/10.1016/j.jhep.2005.01.026Solá S., Ma X., Castro R.E., Kren B.T., Steer C.J., Rodrigues C.M. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor β1-induced apoptosis of rat hepatocytes. J. Biol. Chem. 2003; 278 (49): 48831–48838. https://doi.org/10.1074/jbc.M300468200Solá S., Ma X., Castro R.E., Kren B.T., Steer C.J., Rodrigues C.M. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor β1-induced apoptosis of rat hepatocytes. J. Biol. Chem. 2003; 278 (49): 48831–48838. https://doi.org/10.1074/jbc.M300468200Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R. et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992; 16 (2): 358–364. https://doi.org/10.1002/hep.1840160213Yoshikawa M., Tsujii T., Matsumura K., Yamao J., Matsumura Y., Kubo R. et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992; 16 (2): 358–364. https://doi.org/10.1002/hep.1840160213Zhang H., Xu H., Zhang C., Qiulin Tang, Feng Bi. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov. 2021; 7 (1): 207. https://doi.org/10.1038/s41420-021-00589-8Zhang H., Xu H., Zhang C., Qiulin Tang, Feng Bi. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov. 2021; 7 (1): 207. https://doi.org/10.1038/s41420-021-00589-8Königshofer P., Brusilovskaya K., Petrenko O., Hofer B. S., Schwabl P., Trauner M., Reiberger T. Nuclear receptors in liver fibrosis. Biochim Biophys Acta Mol Basis Dis. 2021; 1867 (12): 166235. https://doi.org/10.1016/j.bbadis.2021.166235Königshofer P., Brusilovskaya K., Petrenko O., Hofer B. S., Schwabl P., Trauner M., Reiberger T. Nuclear receptors in liver fibrosis. Biochim Biophys Acta Mol Basis Dis. 2021; 1867 (12): 166235. https://doi.org/10.1016/j.bbadis.2021.166235Полякова О. А., Остроумова О. Д., Ковалева Г.П., Павлеева Е. Е. Коморбидность неалкогольной жировой болезни печени и сердечно-сосудистых заболеваний: фокус на адеметионин и урсодезоксихолевую кислоту. Медицинский алфавит. 2021; (29): 13–20. https://doi.org/10.33667/2078-5631-2021-29-13-20Polyakova O.A., Ostroumova O.D., Kovaleva G.P., Pavleeva Е.Е. Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid. Medical alphabet. 2021; (29): 13–20. (In Russ.). https://doi.org/10.33667/2078-5631-2021-29-13-20Пахомова И. Г., Кнорринг Г.Ю. Неалкогольная жировая болезнь печени и сердечно-сосудистая патология: особенности ведения пациента на клиническом примере. Экспериментальная и клиническая гастроэнтерология. 2022; 205 (9): 290–297. https://doi.org/10.31146/1682–8658-ecg-205-9-290-297Pakhomova I.G., Knorring G. Yu. Non-alcoholic fatty liver disease and cardiovascular pathology: features of patient management on a clinical example. Experimental and Clinical Gastroenterology. 2022; 205 (9): 290–297. (In Russ.). https://doi.org/10.31146/1682–8658-ecg-205-9-290-297Byrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012; 29 (9): 1098–1107. https://doi.org/10.1111/j.1464–5491.2012.03732.xByrne C.D. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012; 29 (9): 1098–1107. https://doi.org/10.1111/j.1464–5491.2012.03732.xИвашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГГК. 2015; 6: 31–41.Ivashkin V.T., Drapkina O.M., Maev I.V. et al. The prevalence of non-alcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: the results of the study DIREG 2. RZhGGK. 2015; 6: 31–41. (In Russ.).Sayiner M., Koenig A., Henry L., Younossi Z.M. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016; 20: 205–214.Sayiner M., Koenig A., Henry L., Younossi Z.M. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016; 20: 205–214.Koenig A.B., Younossi Z.M., Koenig A.B. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepathology. 2016; 64 (1): 73–84. https://doi.org/10.1002/hep.28431Koenig A.B., Younossi Z.M., Koenig A.B. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepathology. 2016; 64 (1): 73–84. https://doi.org/10.1002/hep.28431Драпкина О.М., Смирин В.И., Ивашкин В.Т. Патогенез, лечение и эпидемиология НАЖБП – что нового? Эпидемиология НАЖБП в России. Русский медицинский журнал. 2011; 28: 1–4.Drapkina O.M., Smirin V.I., Ivashkin V.T. Pathogenesis, treatment and epidemiology of NAFLD – what’s new? Epidemiology of NAFLD in Russia. Russian Medical Journal. 2011; 28: 1–4. (In Russ.).Диагностика и лечение неалкогольной жировой болезни печени / под ред. акад. РАН, проф. В.Т. Ивашкина. Российское общество по изучению печени. М., 2015. 29 с.Diagnosis and treatment of non-alcoholic fatty liver disease / ed. acad. RAS, prof. V.T. Ivashkin. Russian Society for the Study of the Liver. M., 2015. 29 p. (In Russ.).Корнеева О.Н., Драпкина О.М., Буеверов А.О., Ивашкин В. Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клин. персп. гастроэнтерогепатол. 2005; 4: 21–24.Korneeva O.N., Drapkina O.M., Bueverov A.O., Ivashkin V.T. Non-alcoholic fatty liver disease as a manifestation of metabolic syndrome. Clinical Perspectives in Gastroenterology and Hepatology. 2005; 4: 21–24. (In Russ.).Маевская М. В., Котовская Ю. В., Ивашкин В. Т. и соавт. Национальный консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022; 94 (2): 216–253. https://doi.org/10.26442/00403660.2022.02.201363Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T. еt al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. 2022; 94 (2): 216–253. (In Russ.). https://doi.org/10.26442/00403660.2022.02.201363Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020; 73 (1): 202–9. https://doi.org/10.1016/j.jhep.2020.03.039Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020; 73 (1): 202–9. https://doi.org/10.1016/j.jhep.2020.03.039Caligiuri A., Gentilini A., Marra F. Molecular Pathogenesis of NASH. International Journal of Molecular Sciences. 2016; 17 (9): 1575. https://doi.org/10.3390/ijms17091575Caligiuri A., Gentilini A., Marra F. Molecular Pathogenesis of NASH. International Journal of Molecular Sciences. 2016; 17 (9): 1575. https://doi.org/10.3390/ijms17091575Byrne C.D. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc. 2013; 72 (4): 412–419. https://doi.org/10.1017/S0029665113001249Byrne C.D. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc. 2013; 72 (4): 412–419. https://doi.org/10.1017/S0029665113001249Bhatia L.S. et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? European Heart Journal. 2012; (33): 1190–1200. https://doi.org/10.1093/eurheartj/ehr453Bhatia L.S. et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? European Heart Journal. 2012; (33): 1190–1200. https://doi.org/10.1093/eurheartj/ehr453Oni E.T. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230: 258–267.Oni E.T. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230: 258–267.Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl. J. Med. 2010. 363: 1341–1350. https://doi.org/10.1056/NEJMra0912063Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl. J. Med. 2010. 363: 1341–1350. https://doi.org/10.1056/NEJMra0912063Fracanzani A.L., Pisano G., Consonni D. et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease//PLoS ONE. 2016; 11 (9): e0162473. https://doi.org/10.1371/journal.pone.0162473Fracanzani A.L., Pisano G., Consonni D. et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease//PLoS ONE. 2016; 11 (9): e0162473. https://doi.org/10.1371/journal.pone.0162473Nandini M. Meyersohn Th., Mayrhofer K.E., Corey P.S. Douglas U.H., Maros F.S. еt al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. 2021 Jul; 19 (7): 1480–1488. e14. https://doi.org/10.1016/j.cgh.2020.07.030Nandini M. Meyersohn Th., Mayrhofer K.E., Corey P.S. Douglas U.H., Maros F.S. еt al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. 2021 Jul; 19 (7): 1480–1488. e14. https://doi.org/10.1016/j.cgh.2020.07.030Schaffer J.E. Lipotoxicity: Many Roads to Cell Dysfunction and Cell Death: Introduction to a Thematic Review Series. Journal of Lipid Research. 2016; 57 (8): 1327–1328. https://doi.org/10.1194/jlr.E069880Schaffer J.E. Lipotoxicity: Many Roads to Cell Dysfunction and Cell Death: Introduction to a Thematic Review Series. Journal of Lipid Research. 2016; 57 (8): 1327–1328. https://doi.org/10.1194/jlr.E069880Драпкина О.М., Чапаркина С.О. Взаимосвязь метаболического синдрома, асептического воспаления и дисфункции эндотелия. Российские медицинские вести. 2007; 12 (3): 67–75.Drapkina O.M., Chaparkina S.O. Relationship between metabolic syndrome, aseptic inflammation and endothelial dysfunction. Rossijskie medicinskie vesti. 2007; 12 (3): 67–75. (In Russ.).Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78. https://doi.org/10.1053/j.gastro.2015.04.005Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78. https://doi.org/10.1053/j.gastro.2015.04.005Wu P, Zhao J, Guo Y. et al. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020 Aug 27; 529 (3): 834–838.Wu P, Zhao J, Guo Y. et al. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020 Aug 27; 529 (3): 834–838.Dufour JF, Oneta CM, Gonvers JJ. et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006; 4 (12): 1537–43. https://doi.org/10.1016/j.cgh.2006.09.025Dufour JF, Oneta CM, Gonvers JJ. et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006; 4 (12): 1537–43. https://doi.org/10.1016/j.cgh.2006.09.025Simental-Mendía LE, Simental-Mendía M, Sánchez-García A, et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019; 18 (1): 88. https://doi.org/10.1186/s12944-019-1041-4Simental-Mendía LE, Simental-Mendía M, Sánchez-García A, et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019; 18 (1): 88. https://doi.org/10.1186/s12944-019-1041-4Sánchez-García A, Sahebkar A, Simental-Mendía M, SimentalMendía LE. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018; 135: 144–9. https://doi.org/10.1016/j.phrs.2018.08.008Sánchez-García A, Sahebkar A, Simental-Mendía M, SimentalMendía LE. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018; 135: 144–9. https://doi.org/10.1016/j.phrs.2018.08.008Higinio Mappala et al.The efficacy of ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: A 15-year systematic review. Gut. 2019; 68 (Suppl 1): A1–A166.Higinio Mappala et al.The efficacy of ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: A 15-year systematic review. Gut. 2019; 68 (Suppl 1): A1–A166.Trauner M, Claudel T, Fickert P. et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010; 28 (1): 220–4.Trauner M, Claudel T, Fickert P. et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010; 28 (1): 220–4.Корнеева О.Н., Драпкина О.М. Возможности применения урсодезоксихолевой кислоты и статинов для уменьшения сердечно-сосудистого риска у больных с метаболическим синдромом и неалкогольной жировой болезнью печени. Российские медицинские вести. 2011; 16 (3): 57–64.Korneeva O.N., Drapkina O.M. Possibilities of using ursodeoxycholic acid and statins to reduce cardiovascular risk in patients with metabolic syndrome and non-alcoholic fatty liver disease. Russian medical news. 2011; 16 (3): 57–64. (In Russ.).Ахмедов В.А. Метаболические эффекты урсодезоксихолевой кислоты у пациентов с неалкогольной жировой болезнью печени. Лечащий врач. 2024; 4 (27): 71–76. https://doi.org/10.51793/OS.2024.27.4.010Akhmedov V.A. Metabolic effects of ursodeoxycholic acid in patients with non-alcoholic fatty liver disease. Lechaschi Vrach. 2024; 4 (27): 71–76. (In Russ.). https://doi.org/10.51793/OS.2024.27.4.010Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В. и соавт. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 147–152.Martsevich S. Yu., Kutishenko N.P., Drozdova L. Yu., Lerman O.V. et al. A. To study the effect of ursodeoxycholic acid on the efficacy and safety of statin therapy in patients with diseases of the liver, gallbladder and/or biliary tract. Rational pharmacotherapy in cardiology. 2014; 10 (2): 147–152. (In Russ.).Лазебник Л.Б., Голованова Е.В., Туркина С.В. и соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; 185 (1): 4–52. https://doi.org/10.31146/1682–8658-ecg-185-1-4-52Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021; 1 (1): 4–52. (In Russ.). https://doi.org/10.31146/1682–8658-ecg-185-1-4-52Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск XVI / под ред. А.Г. Чучалина (гл. ред.), В.В. Яснецова. М.: Эхо. 2015: 1016.Federal Guidelines on the use of medicines (formulary system). Issue XVI, edited by A.G. Chuchalin (editor-in-chief), V.V. Yasnetsov. M.: Echo, 2015: 1016. (In Russ.).Неалкогольная жировая болезнь печени. Клинические рекомендации МЗ РФ, 2024.Non-alcoholic fatty liver disease. Clinical recommendations of the Ministry of Health of the Russian Federation, 2024. (In Russ.).Хлынов И.Б., Акименко Р.И., Гурикова И.А. и др. Билиарный сладж: опыт терапии в реальной клинической практике. Лечащий врач. 2019; 4: 80–83.Hlynov I.B., Akimenko R.I., Gurikova I.A. et al. Biliary sludge: therapeutic experience in the real clinical practice. Lechaschi Vrach. 2019; 4: 80–83. (In Russ.).Скворцов В.В., Еременко А.А., Виноградова М.В. Современная фармакотерапия при синдроме холестаза. Медицинский совет. 2024; 18 (8): 60–64. https://doi.org/10.21518/ms2024–106Skvortsov VV, Eremenko AA, Vinogradova MV. Modern pharmacotherapy for cholestasis syndrome. Meditsinskiy Sovet. 2024; 18 (8): 60–64. (In Russ.). https://doi.org/10.21518/ms2024–106

The authors declare that there are no conflicts of interest present.